Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 5/20 | 0.45 |
| ▸ | KCNJ11 | Q14654 | 5/20 | 0.45 |
| ▸ | ABCC8 | Q09428 | 4/20 | 0.45 |
| ▸ | KCNJ8 | Q15842 | 4/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | QPCT | Q16769 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7238571 | 0.88 | ABCC9 (0.45) | ABCC9KCNJ11ABCC8KCNJ8GSK3A | |
| SCHEMBL7232889 | 0.82 | ABCC9 (0.52) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL6434872 | 0.82 | ABCC9 (0.65) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7627082 | 0.82 | ABCC9 (0.52) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7232836 | 0.82 | ABCC9 (0.43) | ABCC9KCNJ11ABCC8KCNJ8GSK3A | |
| SCHEMBL7243050 | 0.81 | ABCC9 (0.45) | ABCC9KCNJ11ABCC8KCNJ8GSK3A | |
| SCHEMBL7629532 | 0.81 | ABCC9 (0.43) | ABCC9KCNJ11ABCC8KCNJ8GSK3A | |
| SCHEMBL7239802 | 0.81 | ABCC9 (0.45) | ABCC9KCNJ11ABCC8KCNJ8GSK3A | |
| SCHEMBL7233960 | 0.80 | ABCC9 (0.48) | ABCC9KCNJ11ABCC8KCNJ8GSK3A | |
| SCHEMBL7628655 | 0.80 | ABCC9 (0.50) | ABCC9KCNJ11ABCC8KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |